@fiercebiotech : Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX450-ligand monoclonal antibody missed the main goal of a phase 2 asthma study. $SNY fiercebiotech.com/biotech/sanofi… • TwiCopy

FierceBiotech

@fiercebiotech

+ Follow

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

ID: 18294197

linkhttp://FierceBiotech.com calendar_today21-12-2008 22:21:58

29,29K Tweet

101,101K Takipçi

636 Takip Edilen

FierceBiotech

@fiercebiotech

4 months ago

Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase 2 asthma study. $SNY fiercebiotech.com/biotech/sanofi…

thumb_up_off_alt7

chat_bubble_outline0

repeat3

shareShare